Natera, Inc., a leader in personalized genetic testing and diagnostics, announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease test, at the American Society of Clinical Oncology’s 2022 Gastrointestinal Cancers Symposium.
January 22, 2022
· 5 min read
